Last updated: April 25, 2026
Who supplies atracurium besylate active pharmaceutical ingredient (API)?
Atracurium besylate is marketed globally as an injectable neuromuscular blocking agent. Supply is typically split between (1) API manufacturers and (2) branded/generic injectable product manufacturers that procure API and package finished doses. Publicly accessible supplier lists vary by market, tender window, and regulatory status; the most decision-relevant approach for procurement is to anchor on regulated product dossiers (finished dosage forms) rather than relying solely on API source claims.
Typical supplier set in regulated tenders
In practice, buyers source atracurium besylate through licensed distributors and finished-dose manufacturers. The “supplier” role in procurement documents usually maps to one of these categories:
| Supplier type |
What they supply |
Why it matters for buying |
| Finished-dose manufacturer |
Sterile injectable atracurium besylate in vials |
Matches regulatory labeling, shelf life, and distribution lane |
| Authorized distributor/wholesaler |
Product from branded or generic manufacturers |
Controls availability, cold-chain needs (if any), and lead times |
| Contract manufacturer (CMO) |
Sterile fill-finish, labeling, packaging |
Impacts batch release timeline and supply continuity |
| API supplier |
Atracurium besylate bulk |
Matters for raw-material continuity and potential cost swings |
Operational note: For procurement, finished-dose manufacturers and authorized wholesalers are the actionable suppliers because they can deliver released lots under the buyer’s local regulatory requirements. API suppliers are relevant for long-horizon cost and continuity planning.
Which finished-dose manufacturers commonly sell atracurium besylate injections?
Atracurium besylate injection is marketed under various brand names depending on geography. Procurement documents in hospital and agency markets often list the manufacturer of record on the carton label or in the regulatory submission.
Market-facing brand examples (by geography)
The following branded and generic versions are widely referenced in clinical and regulatory contexts:
- Tracrium (atracurium besylate injection)
- Tensilon / other local brand variants (varies by country)
- Generic atracurium besylate injection (multi-source in most mature markets)
Because supplier eligibility depends on the specific country’s marketing authorization, the practical supplier list for “who can deliver” is the set of finished-dose product owners and their distributors in that jurisdiction.
Which distributors typically supply hospitals and agencies?
Distributors differ by tender region. Common channels include:
- National hospital supply wholesalers
- Emergency-care and anesthesia-focused medical distributors
- Tenders that consolidate supply from a small panel of licensed distributors
For buyers, the decisive input is the distributor of record for the specific lot (as reflected on the invoice, distribution certificate, and batch release documentation).
What documentation procurement should require from suppliers
Across suppliers, procurement typically needs regulatory and quality paperwork that follows the lot delivered:
| Document |
Supplier should provide |
Use in procurement |
| Certificate of Analysis (CoA) |
Per batch or lot |
Confirms assay and impurities match specifications |
| Product license / marketing authorization details |
Confirmed on carton and regulatory listing |
Ensures authorized product for the buyer’s country |
| Batch release documentation |
Lot-specific release |
Confirms release status for sale |
| Sterility and endotoxin documentation |
For sterile injections |
Confirms compliance for parenteral use |
| Expiry, storage conditions, and shipping validation |
Lot-specific |
Locks in usable shelf-life and handling risk |
Why supplier concentration matters for atracurium besylate
Atracurium besylate is a mature, off-patent injectable in many jurisdictions. Supply can still become constrained because of:
- sterile injectables manufacturing capacity (fill-finish and sterile filtration)
- batch release and quality-control throughput
- global API availability and downstream sterile processing windows
In procurement terms, the supply-risk profile is driven more by the finished-dose sterile manufacturing base than by API alone.
How to identify the “real supplier” for lead-time planning
For procurement and contracting, the “supplier” should be defined as the entity that:
- Holds marketing authorization (or is the authorized manufacturer of record) for the finished injectable in the buyer’s country, and
- Can commit to lot availability with guaranteed release dates, and
- Provides batch-level CoA and release documents.
This definition prevents lead-time surprises when distributors re-route product from alternate markets.
Key Takeaways
- Atracurium besylate is procured primarily through finished-dose manufacturers and authorized distributors, not through API-only sourcing in hospital buying cycles.
- The actionable supplier list depends on the buyer’s country marketing authorization and the distributor of record for the delivered lot.
- Procurement should lock on lot-specific release documentation, CoA, sterility/endotoxin evidence, and shelf-life/handling specs.
FAQs
1) Is atracurium besylate typically sourced as API or finished injection for hospitals?
Hospitals and agencies generally buy finished atracurium besylate injection. API sourcing is mostly relevant for manufacturers doing sterile fill-finish.
2) What supplier documentation is most important for each delivered lot?
A lot-specific Certificate of Analysis, batch release documentation, and sterility/endotoxin documentation (with storage conditions and expiry stated for the batch) are the core procurement artifacts.
3) Why can supply tighten even for a mature generic drug?
Supply constraints often come from sterile injectable manufacturing capacity and batch release throughput rather than from patent-driven limits.
4) How do buyers reduce the risk of receiving alternate lots or markets?
Contract for a specific manufacturer of record and product presentation and require batch-level documentation tied to the specific invoice lot.
5) Can the “supplier” in purchase orders differ from the manufacturer on the vial?
Yes. Distributors often appear as suppliers in purchase records, while the vial label identifies the manufacturer of record for the marketed product.
References
- U.S. National Library of Medicine. Drug Label Information: Atracurium Besylate. https://dailymed.nlm.nih.gov/
- European Medicines Agency (EMA). Public assessment and product information for atracurium-related injectable products (where applicable). https://www.ema.europa.eu/
- World Health Organization. WHO Model List of Essential Medicines (context for atracurium as an essential neuromuscular blocker). https://www.who.int/
